Rhythm Pharmaceuticals Competitors

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Volatility and Risk

Rhythm Pharmaceuticals has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Rhythm Pharmaceuticals and Arena Pharmaceuticals, as provided by MarketBeat.

Rhythm Pharmaceuticals currently has a consensus target price of $50.6667, indicating a potential upside of 144.18%. Arena Pharmaceuticals has a consensus target price of $92.80, indicating a potential upside of 37.20%. Given Rhythm Pharmaceuticals' higher possible upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Arena Pharmaceuticals.

Insider & Institutional Ownership

88.4% of Rhythm Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rhythm Pharmaceuticals and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rhythm Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Arena Pharmaceuticals beats Rhythm Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Earnings & Valuation

This table compares Emergent BioSolutions and Rhythm Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Emergent BioSolutions has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Emergent BioSolutions has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Emergent BioSolutions and Rhythm Pharmaceuticals, as provided by MarketBeat.com.

Emergent BioSolutions currently has a consensus price target of $113.6667, indicating a potential upside of 52.63%. Rhythm Pharmaceuticals has a consensus price target of $50.6667, indicating a potential upside of 144.18%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Emergent BioSolutions.

Profitability

This table compares Emergent BioSolutions and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

80.2% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 88.4% of Rhythm Pharmaceuticals shares are owned by institutional investors. 14.1% of Emergent BioSolutions shares are owned by insiders. Comparatively, 9.5% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Emergent BioSolutions beats Rhythm Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Rhythm Pharmaceuticals (NASDAQ:RYTM) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Earnings & Valuation

This table compares Rhythm Pharmaceuticals and I-Mab's revenue, earnings per share (EPS) and valuation.

Rhythm Pharmaceuticals has higher earnings, but lower revenue than I-Mab. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Rhythm Pharmaceuticals and I-Mab, as reported by MarketBeat.com.

Rhythm Pharmaceuticals presently has a consensus target price of $50.6667, indicating a potential upside of 144.18%. I-Mab has a consensus target price of $70.00, indicating a potential upside of 27.06%. Given Rhythm Pharmaceuticals' higher probable upside, equities analysts plainly believe Rhythm Pharmaceuticals is more favorable than I-Mab.

Profitability

This table compares Rhythm Pharmaceuticals and I-Mab's net margins, return on equity and return on assets.

Insider & Institutional Ownership

88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Rhythm Pharmaceuticals beats I-Mab on 6 of the 11 factors compared between the two stocks.

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Earnings & Valuation

This table compares Rhythm Pharmaceuticals and Turning Point Therapeutics' revenue, earnings per share (EPS) and valuation.

Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rhythm Pharmaceuticals has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Rhythm Pharmaceuticals and Turning Point Therapeutics, as reported by MarketBeat.com.

Rhythm Pharmaceuticals presently has a consensus target price of $50.6667, indicating a potential upside of 144.18%. Turning Point Therapeutics has a consensus target price of $153.7143, indicating a potential upside of 102.52%. Given Rhythm Pharmaceuticals' higher probable upside, equities analysts plainly believe Rhythm Pharmaceuticals is more favorable than Turning Point Therapeutics.

Profitability

This table compares Rhythm Pharmaceuticals and Turning Point Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Turning Point Therapeutics beats Rhythm Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Insider & Institutional Ownership

88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 3.2% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Rhythm Pharmaceuticals has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Rhythm Pharmaceuticals and Agios Pharmaceuticals, as reported by MarketBeat.com.

Rhythm Pharmaceuticals presently has a consensus target price of $50.6667, indicating a potential upside of 144.18%. Agios Pharmaceuticals has a consensus target price of $64.6364, indicating a potential upside of 21.13%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Rhythm Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Profitability

This table compares Rhythm Pharmaceuticals and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Rhythm Pharmaceuticals and Agios Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Rhythm Pharmaceuticals has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Rhythm Pharmaceuticals beats Agios Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Insider & Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. 9.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 9.5% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Apellis Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Apellis Pharmaceuticals and Rhythm Pharmaceuticals, as provided by MarketBeat.

Apellis Pharmaceuticals presently has a consensus target price of $124.6154, indicating a potential upside of 180.16%. Rhythm Pharmaceuticals has a consensus target price of $50.6667, indicating a potential upside of 144.18%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Apellis Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Profitability

This table compares Apellis Pharmaceuticals and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Apellis Pharmaceuticals and Rhythm Pharmaceuticals' revenue, earnings per share and valuation.

Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.